Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,764 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus

NCT00308373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin vs Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 13, 2026, 9:22 PM EDT
Not listed Not applicable Interventional

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

NCT02487888
View directory record Official record
Conditions
Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions
Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
Other
Lead sponsor
Proove Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

NCT02229227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Insulin Glargine and Insulin Lispro
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
39
States / cities
Searcy, Arkansas • Huntington Beach, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

NCT01147250
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years and older
Enrollment
6,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
200
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

The VALIDATE-D Study

NCT01635062
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biospecimens for Identification of Diseases of the Pancreas.

NCT01392027
View directory record Official record
Conditions
Pancreatic Cancer, Chronic Pancreatitis, Type II Diabetes, Pancreatic Cysts, Healthy Control
Interventions
Blood Draw
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3502970 in Participants With Type 2 Diabetes

NCT04426474
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3502970, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hialeah, Florida • Marlton, New Jersey • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

NCT01618162
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
44
States / cities
Anaheim, California • Garden Grove, California • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

NCT05462756
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

MedStar Health Type 2 Diabetes Pathway to Control

NCT02925312
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Diabetes Pathway
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Active, not recruiting No phase listed Observational

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

NCT05754281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
2nd Gen LabPatch Glucose Sensing System
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

NCT03724981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide Pen, Semaglutide Pen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Palm Harbor, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Re-Engineered Discharge for Diabetes Care Transitions

NCT06869057
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Social Determinants of Health (SDOH), Hospital Readmission
Interventions
REDDCAT2 Post-Discharge Navigation, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03738865
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Novo Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

NCT01607294
View directory record Official record
Conditions
Hyperlipidemia, Type 2 Diabetes
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

NCT05963594
View directory record Official record
Conditions
Dietary Supplement
Interventions
Oligomalt, maltodextrin
Dietary Supplement
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of Pancreatic Triglyceride Content in Beta-cell Function

NCT00602953
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
No intervention planned.
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

NCT03882970
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Park, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated No phase listed Observational

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

NCT00255645
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
165
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 13, 2026, 9:22 PM EDT